Table 3.
Best response outcomes in 2–12 weeks after radiotherapy, per subgroup
| Response type | Total treated population (n = 432) | Patients < 68 years (n = 234) | All patients with breast or prostate cancer (n = 224) | All patients with spinal metastasesa (n = 289) | Patients in good physical conditionb (n = 202) |
|---|---|---|---|---|---|
| Responders | 262 (61%) | 132 (56%) | 157 (70%) | 172 (60%) | 140 (70%) |
| Complete response | 109 (25%) | 49 (21%) | 71 (32%) | 72 (25%) | 67 (33%) |
| Partial response | 153 (35%) | 83 (36%) | 86 (38%) | 100 (35%) | 73 (36%) |
| Non-responders | 128 (27%) | 78 (33%) | 56 (25%) | 85 (29%) | 53 (26%) |
| Stable pain | 66 (16%) | 42 (18%) | 29 (13%) | 47 (16%) | 27 (13%) |
| Undetermined | 20 (5%) | 9 (4%) | 7 (3%) | 15 (5%) | 8 (4%) |
| Pain progression | 42 (10%) | 27 (11%) | 20 (9%) | 23 (8%) | 18 (9%) |
| Unknown | 42 (10%) | 24 (11%) | 11 (5%) | 32 (11%) | 9 (4%) |
aNumber of patients is lower than the number of spinal lesions; some patients had more than one spinal lesion which needed radiation therapy
bAll patients with WHO performance status of 0 or 1, indicating no or few symptoms